Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > IGMS IGM Biosciences > Detailed Quotes

IGMS IGM Biosciences

18.760
-0.440-2.29%
Close 09/26 16:00 ET
High
19.950
Open
19.200
Turnover
2.76M
Low
18.690
Pre Close
19.200
Volume
144.71K
Market Cap
800.24M
P/E(TTM)
Loss
52wk High
67.140
Shares
42.66M
P/E(Static)
Loss
52wk Low
12.670
Float Cap
223.23M
Bid/Ask %
0.00%
Historical High
133.000
Shs Float
11.90M
Volume Ratio
0.89
Historical Low
12.670
Dividend TTM
--
Div Yield TTM
--
P/B
2.13
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
1.22%
Amplitude
6.56%
Avg Price
19.091
Lot Size
1
Float Cap
223.23M
Bid/Ask %
0.00%
Historical High
133.000
Shs Float
11.90M
Volume Ratio
0.89
Historical Low
12.670
Dividend TTM
--
P/B
2.13
Dividend LFY
--
Turnover Ratio
1.22%
Amplitude
6.56%
Avg Price
19.091
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firm’s product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies, IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies, and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA.
CEO: Mr. Fred Schwarzer
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...